<DOC>
	<DOCNO>NCT01525693</DOCNO>
	<brief_summary>This study gain good understand patient newly diagnose type 2 diabetes treat monitor . The study record information type therapy , therapeutic outcome , patient ' satisfaction .</brief_summary>
	<brief_title>Evaluation Effectiveness Treatment Paradigm Newly Diagnosed Type 2 Diabetes Patients China</brief_title>
	<detailed_description>The prevalence diabetes around world increase 30 million 1985 current 235 million , expect grow 300 million 2030 , 75 percent occur country India China . In China , economic prosperity change diet lifestyle result steep increase prevalence overweight , obesity , diabetes . According late study , adult 20 year age old , incidence diabetes reach 9.7 % prevalence 92.4 million . In nationwide , cross cohort study recently complete China , result show duration diabetes positively correlate incidence CAD microvascular diabetic complication . Preventing diabetes progression prevent onset cardiovascular disease early stage newly diagnosis thus one important goal manage type 2 diabetes . According Chinese Guidelines Prevention Treatment Diabetes , consistent IDF Clinical Guidelines Task Force Global Guideline Type 2 Diabetes , therapeutic target type 2 diabetes define HbA1C &lt; 6.5 % . Various national survey conduct China 2003 , 2004 , 2006 show one forth type 2 diabetes patient China reach therapeutic target.Over recent year , number new antidiabetic treatment , DPP-IV inhibitor , introduce real world practice diabetes management China , create excite opportunity potentially improve glycemic control . UKPDS ( United Kingdom Prospective Diabetes Study ) provide evidence improve glycemic control aggressive treatment western population . There substantial evidence management patient type 2 diabetes . However , believe patient benefit optimal diabetes management China , partially due diversity standard clinical practice complexity diabetes care . For example , unclear treatment regimen work effectively manage newly diagnose type 2 diabetes patient whether aggressive strategy use early stage treatment . Moreover , remain answer factor may influence treatment outcomes . There clearly significant unmet need thus significant opportunity leverage exist medical advancement . This study thus design evaluate current treatment pattern treatment outcomes manage newly diagnose type 2 diabetes patient assess specific unmet need , influence factor , management platform , gap trend practice , provide comprehensive knowledge current management newly diagnose diabetes insight opportunity strategy future research development improve therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>20 year age old Confirmed diagnosis type 2 diabetes make within past 6 month accord 2010 Chinese Guideline Type 2 diabetes Have receive pharmacological treatment T2D , start one regimen switch added hypoglycemic agent Have complete lab test +/ 30 day baseline visit due lab evaluation include HbA1C , serum glucose , lipid profile , routine test Willing return follow visit . Patients willing able return hospital follow visit every 3 month one year enrollment ( e.g . reside locally ) Patients participate another interventional clinical trial Patients willing sign inform consent form</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>diabetes</keyword>
	<keyword>diabetic</keyword>
	<keyword>high glucose</keyword>
	<keyword>Chinese patient</keyword>
</DOC>